Cemiplimab and dupilumab before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of non-small cell lung cancer (NSCLC) or strong signs of it from smoking history and scans.
- You must be at least 18 years old and in good enough health to consider surgery (ECOG score 0-1).
- Your tumor must be at least 1 centimeter and able to be biopsied safely.
- You cannot have an autoimmune disease that required treatment in the past year, or have taken immune-suppressing drugs recently.
- You cannot have a targetable genetic change in your tumor (like EGFR, ALK, or ROS1) unless you have a smoking history.
- You must agree to provide blood samples and have biopsies before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.